Drug Profile
HIV vaccines - Wyeth
Alternative Names: GENEVAX gag-2962; GENEVAX-HIVLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Wyeth
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 24 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral infections pharmacodynamics section
- 30 Sep 2005 The HIV Vaccine Trials Network (HVTN) initiates enrolment in the HVTN 063 trial with Wyeth's HIV DNA vaccine in the US and Brazil